Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial

Open access
Holmes, David R., Savage, Michael, LaBlanche, J.-M., Grip, Lars, Serruys, P.W., Fitzgerald, Peter, Fischman, David, Goldberg, Sheldon, Brinker, Jeffrey A., Zeiher, A.M., Shapiro, Leonard M., Willerson, James, Davis, Barry R., Ferguson, James J., Popma, Jeffrey, King, Spencer B., Lincoff, A. Michael, Tcheng, James E., Chan, Robert, Granett, Jeffrey R., Poland, Marcia · 2002 · Circulation

Abstract

Background— Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after stent placement. No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI. Methods and Results— In this double-blind, randomized, placebo-controlled trial of tranilast (300 and 450 mg BID for 1 or 3 months), 11 484 patients were enrolled. Enrollment and drug were initiated within 4 hours after successful PCI of at least 1 vessel. The primary end point was the first occurrence of death, myocardial infarction, or ischemia-driven target vessel revascularization within 9 months and was 15.8% in the placebo group and 15.5% to 16.1% in the tranilast groups ( P =0.77 to 0.81). Myocardial infarction was the only component of major adverse cardiovascular events to show some evidence of a reduction with tranilast (450 mg BID for 3 months): 1.1% versus 1.8% with placebo ( P =0.061 for intent-to-treat population). The primary reason for not completing treatment was ≥1 hepatic laboratory test abnormality (11.4% versus 0.2% with placebo, P <0.01). In the angiographic substudy composed of 2018 patients, minimal lumen diameter (MLD) was measured by quantitative coronary angiography. At follow-up, MLD was 1.76±0.77 mm in the placebo group, which was not different from MLD in the tranilast groups (1.72 to 1.78±0.76 to 80 mm, P =0.49 to 0.89). In a subset of these patients (n=1107), intravascular ultrasound was performed at follow-up. Plaque volume was not different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm 3 , respectively; P =0.16 to 0.72). Conclusions— Tranilast does not improve the quantitative measures of restenosis (angiographic and intravascular ultrasound) or its clinical sequelae.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000028335.31300.da

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 260

Metadata

Authors
Holmes, D. R., Savage, M., LaBlanche, J.-M., Grip, L., Serruys, P. W., Fitzgerald, P., Fischman, D., Goldberg, S., Brinker, J. A., Zeiher, A. M., Shapiro, L. M., Willerson, J., Davis, B. R., Ferguson, J. J., Popma, J., King, S. B., Lincoff, A. M., Tcheng, J. E., Chan, R., Granett, J. R., & Poland, M.
Venue
Circulation
Published
2002-09-03
Volume
106
Issue
10
Pages
1243-1250
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2154286360
Cited by
260
References
12
FWCI
21.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. https://app.cochat.ai/papers/10.1161/01.cir.0000028335.31300.da
The paper
Holmes, D. R., Savage, M., LaBlanche, J.-M., Grip, L., Serruys, P. W., Fitzgerald, P., Fischman, D., Goldberg, S., Brinker, J. A., Zeiher, A. M., Shapiro, L. M., Willerson, J., Davis, B. R., Ferguson, J. J., Popma, J., King, S. B., Lincoff, A. M., Tcheng, J. E., Chan, R., . . . Poland, M. (2002). Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation. https://doi.org/10.1161/01.cir.0000028335.31300.da

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.